AN2 Therapeutics Receives FDA Clearance for Planned Phase 2 Study
The FDA cleared AN2 Therapeutics’ investigational new drug application to proceed with a planned global Phase 2 study of oral epetraborole in polycythemia vera.
Story updates
12:05:54 PM UTC
SquawkNews
The FDA cleared AN2 Therapeutics’ IND for epetraborole in polycythemia vera. The company has clearance in all planned jurisdictions and expects to initiate the Phase 2 study in Q4 2026.Material DetailsContext by AI AnalystThis is an early-stage clinical development milestone, not evidence of treatm…